BioSpace News Archive

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502) today announced new research collaborations in immuno-oncology (I-O), an area of key strategic focus for the company.

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, announced the company enrolled its first patient in a Phase 2a clinical trial evaluating vibegron in patients with abdominal pain due to irritable bowel syndrome (IBS) on December 31, 2018.

Tarveda Therapeutics, a clinical stage biopharmaceutical company discovering and developing a new class of potent and selective miniature drug conjugates (Pentarins®) for the treatment of patients with a wide range of solid tumors today announced that Drew Fromkin, President and Chief Executive Officer, will present at the 11th Annual Biotech Showcase, occurring January 7-9, 2019 at the Hilton Union Square in San Francisco.

GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced positive results from a clinical trial supporting the efficacy and safety profile of a new treatment, GammaTile™ Therapy, for patients with recurrent, previously treated brain tumors known as meningiomas.

It is expected that the Scheme will become effective, and that closing of the Acquisition will take place, on January 8, 2019

Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that it has dosed the first cohort of subjects in a Phase 1 clinical study evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of anti-fibrotic agent PLN-74809.

Genevant Sciences, a leading biopharmaceutical company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics across multiple modalities, announced today that its President & CEO Dr. Bo Rode Hansen will present a corporate update on Monday, January 7, 2019,

Initiation of clinical studies with TTX-030 is targeted in Q1 2019

Barry joined NuVasive as CEO on November 5, 2018.

Ms. DiCicco is an experienced C-suite executive and a corporate director with an array of leadership accomplishments at both public and private companies.